Cargando…

Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis

BACKGROUND: This study evaluated the risk factors of long-term mortality in patients with multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) in South Korea who were lost to follow-up (LTFU). METHODS: This was a retrospective longitudinal follow-up study using an integrated database constructed...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hongjo, Mok, Jeongha, Ae Kang, Young, Jeong, Dawoon, Kang, Hee-Yeon, Kim, Hee Jin, Kim, Hee-Sun, Jeon, Doosoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423986/
https://www.ncbi.nlm.nih.gov/pubmed/37583964
http://dx.doi.org/10.1183/23120541.00135-2023
Descripción
Sumario:BACKGROUND: This study evaluated the risk factors of long-term mortality in patients with multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) in South Korea who were lost to follow-up (LTFU). METHODS: This was a retrospective longitudinal follow-up study using an integrated database constructed by data linkage of the three national databases, which included 7226 cases of MDR/RR-TB notified between 2011 and 2017 in South Korea. Post-treatment outcomes of patients who were LTFU were compared with those of patients who achieved treatment success. RESULTS: Of the 7226 MDR/RR-TB cases, 730 (10.1%) were LTFU. During a median follow-up period of 4.2 years, 101 (13.8%) of the LTFU patients died: 25 deaths (3.4%) were TB related and 76 (10.4%) were non-TB related. In the LTFU group, the adjusted hazard ratio (aHR) of all-cause mortality (aHR 2.50, 95% CI 1.99–3.15, p<0.001), TB-related mortality (aHR 5.38, 95% CI 3.19–9.09, p<0.001) and non-TB-related mortality (HR 2.21, 95% CI 1.70–2.87, p<0.001) was significantly higher than that in the treatment success group. Independent risk factors for all-cause mortality in the LTFU group were age >55 years, fluoroquinolone resistance, cancer and no retreatment. In the LTFU patients who did not receive retreatment, the risk of non-TB-related mortality (aHR 5.00, 95% CI 1.53–16.37, p=0.008) and consequent all-cause mortality (aHR 2.18, 95% CI 1.08–4.40, p=0.030) was significantly higher than that of patients who received retreatment. CONCLUSION: Non-TB-related mortality was the main cause of death and might be reduced by retreatment in LTFU patients with MDR/RR-TB.